Critical Care Copilot is Alnitak's own product. A clinician speaks the ICU shift handover they already give, in whichever language they think in, and receives a structured SBAR note they review twice and sign before leaving the unit. It transcribes and structures; it never decides. Alnitak built the product, the marketing site, the attribution and funnel instrumentation, and the internal studio the team uses to produce reviewed content.
Handover is a doctor-to-doctor conversation with a fixed structure, given out loud and written up later from memory at a desk. Whatever falls out between the bedside and the desk falls out silently, and a verbal handover leaves no record of what was said or not said.
Published research on handovers between staff intensivists found the incoming clinician correctly identified 53% of diagnoses and 40% of treatment goals. Every ambient scribe on the market documents a doctor-patient consultation and produces prose. Nobody was building for the handover itself.
Requirements came from buyer research, not a feature list. The person with the most pain, the registrar giving 20 to 40 handovers a month, has the least money and no authority; the person with the budget gives four. That mismatch set the pricing, the free tier and the decision to sell the unit rather than the seat.
Four fears named by clinicians each own a section of the product: the field nobody covered stays visibly empty instead of being filled in fluently; a full audit trail answers the fear of blame; differential-diagnosis features were removed so the product sells typing, never thinking; and a dedicated cleanup stage handles English clinical terms inside Arabic speech.
Five claims govern every sentence, and any line that supports none of them is cut. Three tone tests and a banned-word list keep the copy from sounding like a vendor. The call to action is built around permission and occasion: try it on tonight's handover, no card, no IT approval. The FAQ was replaced by an objection block, with compliance claims gated on shipped reality.
Channels are ranked by how professionals actually adopt: WhatsApp as the referral engine, founder-led artefacts on X including the product's own failure cases, LinkedIn paid for the consultant tier only, Meta for retargeting only. The clinician co-founder writes in the first person; the company page never does.
The system was built before the spend. Every posted link goes through a branded route that expands into full attribution, separates owned posts from peer referrals, tells one WhatsApp group from another and preserves platform click identifiers. Analytics sit behind consent and conversion events are sent both from the browser and server-side. Six funnel events end in the one that means real use: a signed handover.
Paid was sized against real cost-per-click and found unable to be the engine, so the plan holds it for retargeting and one conference-week burst, and the first twenty habitual users are acquired by hand. That discipline, not a spend number, is the story so far.
Tested with 15 clinicians on simulated cases. Landing, attribution and funnel instrumentation live. Paid acquisition withheld until in-country hosting and de-identification are live. Results will be published when they exist, attributable to the channel and the post that produced them.
Fifteen clinicians have tested the product on simulated cases. The landing page, pilot page, security page and sample output are live, and every posted link is attributable to a channel, a group and a post. Paid acquisition is deliberately withheld until the compliance items that gate it are closed, so no spend or conversion figures are claimed yet. What exists is the system that makes the first dollar of spend accountable.
Building a product for a demanding professional audience? We can run the same research-led, instrumented go-to-market for you.